NewIntroducing the StillHer Clarity Kit — the complete cascade protocolExplore the Kit →
PRODUCT GUIDE • SUPPLEMENT COMPARISON

Nutrafol vs Viviscal vs Biotin:
Which Actually Works for Menopause Hair Loss?

You have three tabs open. You have read the ingredient lists. Nobody has given you a straight answer that accounts for the fact that you are in menopause. This article is that answer.

Samantha Jones
Samantha Jones, Research Advocate · Updated April 14, 2026 · 14 min read
Nutrafol Women’s Balance is the only hair supplement with a published double-blind, placebo-controlled trial specifically in menopausal women.

Viviscal has clinical data in women with general thinning but no menopause-specific study. Biotin has no published RCTs for hair loss in non-deficient women. If your hair loss is driven by the hormonal cascade of menopause — and if you are choosing a supplement — the published evidence points in one direction.

Affiliate Disclosure: StillHer earns a commission on Nutrafol purchases through links in this article. This does not influence evidence-based rankings. Full disclosure: StillHer Affiliate Policy.

The Head-to-Head Comparison

Nutrafol Women’s BalanceViviscalBiotin (standalone)
RCT in menopausal womenYes (n=70, 6-month + 12-month)No (general thinning only)No
Menopausal-specific formulaYes (maca, extra saw palmetto, astaxanthin)NoNo
Targets DHTYes (saw palmetto — 5α-reductase inhibition)NoNo
Targets cortisol/stressYes (Sensoril ashwagandha)NoNo
Key active mechanismMulti-pathway: DHT + cortisol + inflammationAminoMar marine complex (nutritional)Cofactor for keratin (only if deficient)
Timeline to results3–6 months3–6 monthsNo proven timeline
Safe with HRTYesYesYes
Interferes with lab testsNoNoYes (thyroid panels, troponin)
Price/month~$88~$33–50$5–20
VerdictBest evidence for menopauseReasonable if saw palmetto intolerantOnly if deficiency confirmed

Nutrafol Women’s Balance — The Evidence

Nutrafol Women’s Balance

MODERATE — MENOPAUSE-SPECIFIC

A 6-month randomized, double-blind, placebo-controlled trial enrolled 70 perimenopausal, menopausal, and postmenopausal women (ages 40–65) with self-perceived thinning. The active group showed progressive increases in terminal, vellus, and total hair counts at both 90 and 180 days compared to placebo, with significantly less shedding and blinded-physician-confirmed improvement in growth and quality. (Ablon, JDD, 2021)

A 12-month extension followed: when the placebo group switched to the active supplement, they experienced the same improvements. Women on the supplement for the full 12 months saw a 13.4% increase in terminal hairs (from 68.1 to 77.2 mean count) and an 11.7% increase in total hairs. No adverse events were reported. (Ablon et al., JDD, 2022)

The formulation specifically targets the menopausal cascade: saw palmetto inhibits 5-alpha reductase (reducing DHT conversion), Sensoril ashwagandha lowers cortisol (which drives stress-related shedding), BCM-95 curcumin addresses follicular inflammation, and maca supports hormonal balance during the transition. This is a meaningful design distinction — it was built for the biology of menopause, not retrofitted from a general formula.

Strengths

  • Only supplement with menopause-specific RCT
  • Multi-pathway mechanism (DHT + cortisol + inflammation)
  • Safe with HRT and minoxidil
  • Drug-free, no prescription needed
  • 12-month data showing continued improvement

Limitations

  • ~$88/month (premium price point)
  • 4 capsules per day
  • Industry-funded trial, relatively small sample
  • 3–6 month minimum before visible results
RECOMMENDED FOR MENOPAUSE

The only supplement with published clinical data in menopausal women. Targets the DHT cascade, cortisol, and inflammation simultaneously. Drug-free. Safe to combine with minoxidil and HRT.

SEE CLINICAL RESULTS

Viviscal — The Evidence

Viviscal

HAS CLINICAL DATA

Viviscal has been studied in 12+ clinical trials over 25 years. The key ingredient is AminoMar, a proprietary marine complex (shark and mollusk powder) combined with horsetail-derived silica, vitamin C, biotin, and zinc. Multiple placebo-controlled studies in women with “self-perceived thinning hair” have shown significant increases in terminal hair counts at 90 and 180 days. (Ablon, JCAD, 2012; Rizer et al., 2015)

The critical distinction: none of these trials specifically enrolled menopausal women or controlled for menopausal hormonal status. Participants were women aged 21–75 with thinning attributed to “poor diet, stress, hormonal influences, or abnormal menstrual cycles” — a broad umbrella that may or may not capture your specific situation.

Viviscal’s mechanism is primarily nutritional rather than hormonal. It does not contain DHT-blocking ingredients (no saw palmetto), does not target cortisol, and does not address the estrogen-androgen imbalance that drives menopausal hair loss specifically. A 2022 Bayesian network meta-analysis ranked Nutrafol higher than Viviscal for efficacy in women at 24 weeks. (Front Med, 2022)

Strengths

  • Multiple published studies showing hair count improvements
  • Lower cost (~$33–50/month)
  • Well-tolerated, long track record
  • Suitable if you cannot tolerate saw palmetto

Limitations

  • No menopause-specific trial data
  • Does not target DHT or cortisol
  • Contains marine-derived ingredients (not suitable for shellfish allergies or strict plant-based diets)
  • Study populations included women with temporary, diet-related thinning — not necessarily your situation

Biotin — Why It’s Probably Not Your Answer

Biotin (Standalone)

LIMITED EVIDENCE

Biotin (vitamin B7) is a cofactor for carboxylase enzymes involved in keratin production. It is the most marketed hair supplement and the one with the weakest evidence for the specific context of menopause. There are no published randomized controlled trials showing biotin supplementation improves hair growth in women who are not biotin-deficient. Actual biotin deficiency is rare in adults eating a varied diet.

More concerning: high-dose biotin supplementation interferes with immunoassay-based laboratory tests, including thyroid panels (TSH, free T3, free T4) and cardiac troponin. For midlife women who need accurate thyroid monitoring — and thyroid dysfunction is itself a cause of hair loss — this is not a trivial side effect. The FDA issued a safety communication about biotin interference with lab tests in 2017 and updated it in 2019.

Strengths

  • Inexpensive ($5–20/month)
  • Widely available
  • Effective if you have confirmed biotin deficiency

Limitations

  • No RCTs for hair loss in non-deficient women
  • Does not address any step of the menopausal cascade
  • Interferes with thyroid and cardiac lab tests
  • Deficiency is rare in adults eating a varied diet

The honest verdict: If your hair loss is driven by menopausal hormonal changes — declining estrogen, rising DHT, elevated cortisol — then a supplement designed to address those specific drivers has a biological rationale that Viviscal and biotin do not. Nutrafol Women’s Balance is the only option that has both the mechanistic design and the published clinical data in your specific population.

That said, supplements are one piece of the strategy. The full treatment ranking covers minoxidil, spironolactone, LLLT, PRP, and HRT — all of which have stronger or complementary evidence. No supplement replaces a dermatology evaluation.

A note for breast cancer survivors: Nutrafol Women’s Balance contains phytoestrogen-containing ingredients. If you have a history of hormone-receptor-positive breast cancer, discuss with your oncologist before starting any supplement that influences hormonal pathways. Viviscal and biotin do not have hormonal mechanisms and are generally considered safe regardless of history.
SKIN & HAIR SERIES
Samantha Jones
Samantha Jones, Research AdvocateSamantha is the editorial voice of StillHer. She translates clinical research into plain language for women navigating perimenopause and menopause. She is not a licensed clinician — her authority comes from evidence, not credentials. Read her story.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting any supplement. Samantha Jones is a research advocate, not a licensed clinician. This article contains 1 affiliate link; StillHer only recommends products whose evidence base we can defend independently.

Frequently Asked Questions

Nutrafol Women’s Balance is the only hair supplement with a published placebo-controlled trial specifically in menopausal women (n=70, 6-month + 12-month). Viviscal has clinical data in women with general thinning but no menopause-specific study. Nutrafol’s formulation also targets DHT and cortisol — the hormonal drivers of menopausal hair loss — while Viviscal’s mechanism is primarily nutritional. A 2022 Bayesian network meta-analysis ranked Nutrafol higher than Viviscal for efficacy in women at 24 weeks. (Ablon, JDD, 2021; Front Med, 2022)
There are no published randomized controlled trials showing biotin improves hair growth in women who are not biotin-deficient. Actual biotin deficiency is rare in adults eating a varied diet. High-dose biotin also interferes with thyroid and cardiac lab tests, which is a meaningful concern for midlife women who need accurate lab monitoring. Biotin does not address any step of the estrogen-DHT-follicle cascade that drives menopausal hair loss.
Yes. Nutrafol Women’s Balance is drug-free and has no known interactions with minoxidil or HRT. They target different pathways: Nutrafol addresses DHT, cortisol, and inflammation internally; minoxidil stimulates follicles topically; HRT restores estrogen and progesterone systemically. Many dermatologists recommend combining these approaches.
At approximately $88 per month, Nutrafol Women’s Balance costs more than Viviscal (~$33–50) or standalone biotin ($5–20). The price reflects the clinical testing (the only menopause-specific RCT for a supplement), patented ingredient standardization (Synergen Complex Plus), and the multi-pathway formulation. Whether it is “worth it” depends on whether you value menopause-specific evidence over a lower price point with less targeted data.
In the published clinical trial, menopausal women showed progressive improvement at both 3 and 6 months, with continued gains through 12 months. Most women notice reduced shedding first (often by month 2–3), followed by visible improvement in density and coverage by months 4–6. Hair growth is slow biology — consistency matters more than any other variable.
Viviscal is generally considered safe and well-tolerated. It does not contain hormonal ingredients. It is suitable for women who cannot tolerate saw palmetto (which is in Nutrafol) or who follow a non-vegan diet (Viviscal contains marine-derived AminoMar). It is not suitable for women with shellfish allergies. While safe, it does not specifically target the hormonal drivers of menopausal hair loss.

The StillHer Clarity Kit

Supplements are one piece. Your hormones are the system.

The Clarity Kit maps every symptom to its hormonal driver, prepares your lab checklist, and gives you the framework to evaluate any product or protocol with confidence.

Get the Clarity Kit — $27